1. Scrip
  2. >>New Products

Eisai Forecasts Surging Leqembi Sales In Its New Fiscal Year

Launch Progresses In US, Japan And Beyond

 
• By Mandy Jackson

Eisai expects growth to JPY56.5bn ($364.7m) in fiscal year 2024 from JPY4.3bn ($27.8m) in FY 2023. The company initiated a rolling BLA submission for subcutaneous Leqembi as maintenance therapy and expects approval in 2025.

Rapid growth of economic indicators. rapid growth of financial indicators of economy. economic and financial growth.
Leqembi growth will come largely from US sales, but also from Japan and other countries • Source: Shutterstock

Eisai Co., Ltd.'s most closely watched drug – the anti-amyloid antibody Leqembi (lecanemab) – contributed little revenue in the fiscal year that ended on 31 March, but the Japanese big pharma expects a big ramp up in the new year. 

The firm reported JPY741.8bn ($4.79bn) in fiscal year 2023 revenue, essentially flat relative to FY 2022 revenue of JPY744.4bn ($4.81bn),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

PTC Projects Confidence In Sephience Launch With Royalty Buyback

 
• By Manas Mishra

The company will start shipping its newly launched phenylketonuria drug within two weeks and has bought back global net sales obligations for the treatment.

Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted

 
• By Jessica Merrill

The accelerated approval came three months after Jazz completed the acquisition of Modeyso’s developer, Chimerix.

S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas

 
• By Jessica Merrill

Ultragenyx updated investors on interactions with the US FDA on gene therapy, while new drug launches were themes for Ionis and Organon in Q2 reporting.

Pipeline Watch: Ten Approvals And Fourteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Executives On The Move: Changes At The Top At Novo Nordisk Plus Other New CEOs

Flashpoint Therapeutics and Nerviano Medical Sciences (Shanghai) have new leaders, while Genmab hires an ex-Gilead Sciences executive.

Lilly Confident In Orforglipron Despite Disappointing Phase III Data

 
• By Mandy Jackson

Lilly spent much of its earnings call defending orforglipron as analysts lamented its results in obesity versus Novo’s semaglutide, overshadowing strong Q2 revenue growth driven by existing GLP-1/GIP franchise Mounjaro/Zepbound.

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.